Mylan Italia S.r.l Pharmaceutical Import Profile — Italy (DGFT 2022–2026)

Name: Mylan Italia S.r.l Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Italia S.r.l — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Mylan Italia S.r.l

Pharmaceutical Importer · Italy · Lipid & Metabolism Focus · $1.4M Total Trade · DGFT Verified

Mylan Italia S.r.l is a pharmaceutical importer based in Italy with a total trade value of $1.4M across 2 products in 1 therapeutic categories. Based on 44 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mylan Italia S.r.l sources from 8 verified Indian suppliers, with Mylan Laboratories Limited accounting for 72.2% of imports.

Mylan Italia S.r.l — Import Portfolio & Supplier Network

Mylan Italia S.r.l import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Italia S.r.l?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$6.1M	279	72.2%
Granules India Limited	$1.7M	41	20.2%
Lupin Limited	$300.0K

What Formulations Does Mylan Italia S.r.l Import?

Formulation	Value	Ships
Metformin tab1000mg 60bl it myg	$600.0K	12
Metformin TAB 1000MG 60bl it myg	$550.3K	12
Harmless medicines, zolpeduar 5 MG	$550.0K	11
Clopidogrel e acido acetilsalicilico	$450.0K	9
Harmless medicines, zolpidem TAB 10MG	$400.0K	8
Harmless medicines, clopidogrel e	$300.0K	6
Harmless medicines, zolpidem tartrate	$250.0K	5
Harmless medicines, ezetimibe e	$201.7K	5
Levetiracetam mylan gen 500MG 60s	$200.0K	4
Lansoprazolo mylan generics italia 15MG	$159.3K	4
Metformin TAB 500MG 30bl it myg metformina mylan generics 500MG	$147.2K	4
Harmless medicines, sitagliptin mylan	$124.1K	4
Harmless medicines, lansoprazolo mylan	$120.8K	4
Metformin TAB 500MG 50bl it myg	$100.0K	2
Sitagliptin mylan 100 MG 28 bl TAB	$100.0K	2

Mylan Italia S.r.l imports 199 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Allopurinol	Lipid & Metabolism	$898.0K	33	0.2%	11
2	Ezetimibe	Lipid & Metabolism	$550.0K	11	0.1%	17

Mylan Italia S.r.l imports 2 pharmaceutical products across 1 categories into Italy totaling $1.4M.

Mylan Italia S.r.l — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Italia S.r.l., now operating under the name Viatris Italia S.r.l., is a pharmaceutical company based in Milan, Italy. It functions as a pharmaceutical importer and buyer, specializing in the wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is a subsidiary of Viatris Inc., a global healthcare organization formed in November 2020 through the merger of Mylan and Upjohn, Pfizer's off-patent medicine division. (viatris.it)

Viatris Italia S.r.l. plays a significant role in Italy's pharmaceutical distribution network, sourcing a diverse range of pharmaceutical products from international suppliers to meet the domestic market's needs. The company's operations are characterized by a focus on importing finished pharmaceutical formulations, ensuring a steady supply of essential medications to the Italian healthcare system.

2Distribution Network

Viatris Italia S.r.l. maintains a centralized distribution network with its headquarters located at Via Vittor Pisani 20, 20124 Milan, Italy. (ufficiocamerale.it) While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Milan suggests access to major transportation hubs, facilitating efficient distribution across Italy and potentially to other European markets. The proximity to Milan's international airports and seaports likely supports the company's logistics operations, enabling timely delivery of pharmaceutical products to meet market demands.

3Industry Role

Viatris Italia S.r.l. operates primarily as a pharmaceutical importer and wholesaler within Italy's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from international suppliers, the company ensures a consistent supply of medications to the Italian market. This role is crucial in bridging the gap between global pharmaceutical manufacturers and the domestic healthcare system, contributing to the availability of a wide range of therapeutic options for patients and healthcare providers in Italy.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Italia S.r.l

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Viatris Italia S.r.l. demonstrates a high degree of sourcing concentration, with a total import value of $1.4 million USD from India across 44 shipments, importing 199 unique formulations. The top five products imported include Allopurinol ($898K) and Ezetimibe ($550K), accounting for 100% of the company's imports. This indicates a strategic focus on specific therapeutic areas, particularly within lipid and metabolism disorders.

The company's primary supplier is Mylan Laboratories Limited, accounting for 72.2% of the total import value, followed by Granules India Limited at 20.2%. This concentration suggests a strong, strategic partnership with these suppliers, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chains. However, the reliance on a limited number of suppliers also introduces risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting trade relations.

2Supply Chain Resilience

Viatris Italia S.r.l.'s supply chain resilience is closely tied to its partnerships with key Indian suppliers, notably Mylan Laboratories Limited and Granules India Limited. The company's import data indicates a diverse range of 199 unique formulations, suggesting a broad product portfolio that may mitigate risks associated with dependency on a single product line. However, the heavy reliance on a few suppliers could pose challenges in the event of supply chain disruptions, regulatory changes, or geopolitical tensions affecting trade relations.

Importing Pharmaceuticals into Italy — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Italy

1Regulatory Authority & Framework

In Italy, the primary regulatory authority overseeing pharmaceutical imports is the Italian Medicines Agency (AIFA). AIFA is responsible for evaluating and authorizing the importation of pharmaceutical products, ensuring they meet the necessary safety, efficacy, and quality standards. The agency's guidelines stipulate that import requests must be initiated by health facilities or Territorial Pharmacy Services affiliated with the National Health Service (NHS), rather than by private citizens or associations. (aifa.gov.it)

Key legislation governing pharmaceutical imports into Italy includes the Ministerial Decree of 11 May 2001, which outlines the procedures for importing medicines, particularly in cases of shortages. This decree specifies that import authorizations can only be issued upon request from authorized health entities, ensuring that imported medicines are integrated into the national healthcare system appropriately. (aifa.gov.it)

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Italy are stringent, necessitating that all imported medicines possess a valid marketing authorization from AIFA. This ensures that imported products comply with Italian and European Union regulations concerning safety, efficacy, and quality. Additionally, imported pharmaceutical products must be manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards recognized by the European Union, WHO, or PIC/S. This certification guarantees that manufacturing processes meet high-quality standards, safeguarding public health.

Mylan Italia S.r.l — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Viatris Italia S.r.l.'s product strategy focuses on importing pharmaceutical formulations within the lipid and metabolism therapeutic category, with Allopurinol and Ezetimibe being the top imported products. This focus aligns with the company's strategic objectives to address prevalent health conditions in Italy, such as gout and hypercholesterolemia. The decision to import these specific therapeutic areas is likely driven by market demand, as these conditions are common in the Italian population, necessitating a consistent supply of effective treatments.

The company's emphasis on these therapeutic areas also reflects a strategic approach to meet the healthcare needs of the Italian market, ensuring that essential medications are readily available to patients and healthcare providers. By concentrating on specific therapeutic categories, Viatris Italia S.r.l. can optimize its supply chain and distribution processes, enhancing efficiency and responsiveness to market demands.

2Sourcing Profile

Viatris Italia S.r.l. employs a sourcing strategy that focuses on importing generic pharmaceutical formulations from India, particularly from suppliers like Mylan Laboratories Limited and Granules India Limited. This approach allows the company to offer cost-effective medications while maintaining quality standards. The preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) indicates a strategic decision to streamline operations and ensure a consistent supply of ready-to-use products.

Frequently Asked Questions — Mylan Italia S.r.l

What products does Mylan Italia S.r.l import from India?

Mylan Italia S.r.l imports 2 pharmaceutical products across 1 categories. Top imports: Allopurinol ($898.0K), Ezetimibe ($550.0K).

Who supplies pharmaceuticals to Mylan Italia S.r.l from India?

Mylan Italia S.r.l sources from 8 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (72.2% of imports, $6.1M).

What is Mylan Italia S.r.l's total pharmaceutical import value?

Mylan Italia S.r.l's total pharmaceutical import value from India is $1.4M, based on 44 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Italia S.r.l focus on?

Mylan Italia S.r.l imports across 1 categories. The largest: Lipid & Metabolism (100.0%).

Get Full Mylan Italia S.r.l Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Mylan Italia S.r.l

Mylan Italia S.r.l — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Mylan Italia S.r.l?

What Formulations Does Mylan Italia S.r.l Import?

What Products Does Mylan Italia S.r.l Import?

Top Products by Import Value

Mylan Italia S.r.l Therapeutic Categories — 1 Specializations